Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/21718
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sinnaeve, Peter R. | - |
dc.contributor.author | Danays, Thierry | - |
dc.contributor.author | BOGAERTS, Kris | - |
dc.contributor.author | Van de Werf, Frans | - |
dc.contributor.author | Armstrong, Paul W. | - |
dc.date.accessioned | 2016-07-12T13:09:12Z | - |
dc.date.available | 2016-07-12T13:09:12Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | DRUGS & AGING, 33 (2), p. 109-118 | - |
dc.identifier.issn | 1170-229X | - |
dc.identifier.uri | http://hdl.handle.net/1942/21718 | - |
dc.description.abstract | Elderly patients constitute a large and growing proportion of ST-elevation myocardial infarction (STEMI) patients, yet they have been under-represented or even excluded from reperfusion trials. Despite evidence that fibrinolysis improves outcomes irrespective of age, many elderly STEMI patients still remain undertreated or subject to major delays to primary percutaneous coronary intervention (PCI). The fear of an excessive risk of intracranial hemorrhage (ICH) in these patients can lead to avoidance of potentially life-saving reperfusion treatment, despite the fact that current STEMI guidelines do not exclude the elderly from a pharmaco-invasive strategy. Age-specific dose reductions have been succesfully made to antithrombotic drugs such as clopidogrel and enoxaparin as an adjunct to fibrinolysis, but until recently no dose adjustments for elderly patients have been applied to the fibrinolytic agents. In the pharmaco-invasive STREAM trial, halving the bolus of tenecteplase for patients aged >75 years because of an unacceptably high ICH rate in the elderly was associated with a more favorable safety/efficacy profile. Whether a pharmaco-invasive strategy including half-dose tenecteplase, age- and weight-adjusted enoxaparin, and a tailored P2Y(12) inhibitor followed by routine angiography represents a safe and efficacious alternative reperfusion therapy for elderly patients remains to be prospectively assessed in a clinical trial in this age group. | - |
dc.description.sponsorship | Paul W. Armstrong has received honorarium and a grant from Boehringer Ingelheim. Thierry Danays is an employee of Boehringer Ingelheim, France. Kris Bogaerts has received consulting and travel fees through his institution for statistical consulting and support to data monitoring committees for studies by Boehringer Ingelheim. Frans Van de Werf has received grants for multicenter studies with fibrinolytic agents (mainly tenecteplase) supported by Boehringer Ingelheim, and consulting fees/honoraria, payments for lectures, and travel support from Boehringer Ingelheim and AstraZeneca. Peter R. Sinnaeve has no conflicts that might be relevant to the contents of this manuscript. | - |
dc.language.iso | en | - |
dc.publisher | ADIS INT LTD | - |
dc.rights | © Springer International Publishing Switzerland 2016 | - |
dc.title | Drug Treatment of STEMI in the Elderly: Focus on Fibrinolytic Therapy and Insights from the STREAM Trial | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 118 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 109 | - |
dc.identifier.volume | 33 | - |
local.format.pages | 10 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Sinnaeve, Peter R.; Van de Werf, Frans] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven, Belgium. [Danays, Thierry] Boehringer Ingelheim GmbH & Co KG, Reims, France. [Bogaerts, Kris] Katholieke Univ Leuven, Interuniv Inst Biostat & Stat Bioinformat, Leuven, Belgium. [Bogaerts, Kris] Univ Hasselt, Hasselt, Belgium. [Armstrong, Paul W.] Univ Alberta, Canadian Virtual Coordinating Ctr Global Collobor, Edmonton, AB, Canada. | - |
local.publisher.place | NORTHCOTE | - |
local.type.refereed | Refereed | - |
local.type.specified | Review | - |
dc.identifier.doi | 10.1007/s40266-016-0345-6 | - |
dc.identifier.isi | 000370382800004 | - |
item.validation | ecoom 2017 | - |
item.contributor | Sinnaeve, Peter R. | - |
item.contributor | Danays, Thierry | - |
item.contributor | BOGAERTS, Kris | - |
item.contributor | Van de Werf, Frans | - |
item.contributor | Armstrong, Paul W. | - |
item.accessRights | Restricted Access | - |
item.fullcitation | Sinnaeve, Peter R.; Danays, Thierry; BOGAERTS, Kris; Van de Werf, Frans & Armstrong, Paul W. (2016) Drug Treatment of STEMI in the Elderly: Focus on Fibrinolytic Therapy and Insights from the STREAM Trial. In: DRUGS & AGING, 33 (2), p. 109-118. | - |
item.fulltext | With Fulltext | - |
crisitem.journal.issn | 1170-229X | - |
crisitem.journal.eissn | 1179-1969 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
sinnaeve2016.pdf Restricted Access | Published version | 730.83 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
3
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
3
checked on May 1, 2024
Page view(s)
78
checked on Sep 7, 2022
Download(s)
44
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.